June Wasser currently serves as a consultant to organizations on health science policy and engagement. As former Executive Director of the Reagan-Udall Foundation for the FDA she provided leadership for the Foundation’s development of initiatives intended to foster advances in regulatory science in support of the FDA’s mission. Ms. Wasser built strategic relationships throughout the public and private sectors with the goal of developing a portfolio of unique programs that complement and enhance the priorities and activities of the FDA such as: Innovations in Medical Evidence Development and Surveillance which serves to advance the science necessary to support post-market evidence generation on regulated products and an Expanded Access Navigator that aims to increase knowledge around the use of patient access to investigational drugs for patients facing life-threatening illnesses. She also created the Innovations in Regulatory Science Awards program to recognize leaders in the regulatory field.
Precision medicine has incredible promise for patients. Enormous amounts of money and time are invested in developing technologies and targeted therapies. Genomics, proteomics, phosphorylation assays, RNA expression, organoid growth, and testing, and even delicate mass measurement of liquid cancer cells are explored. This innovation must be focused to maximize the benefit to the most important participants in our healthcare system, the patient. This track is about putting patient needs first, and understanding and accessing the latest (cancer) treatment options.